Literature DB >> 3332102

Role of chromosomal abnormalities in chronic lymphocytic leukemia.

G Gahrton1, G Juliusson, K H Robèrt, K Friberg.   

Abstract

Chromosomal aberrations occur in both B-CLL and T-CLL. The polyclonal B-cell mitogens, in particular Epstein-Barr virus and lipopolysaccharide from E. coli, have been used successfully to reveal chromosomal abnormalities in 40-60% of patients with B-CLL, while T-cell mitogens have shown chromosomal aberrations in T-CLL. The most common clonal chromosomal aberration in B-CLL is an extra chromosome 12, alone or together with other abnormalities. Other common aberrations are 14q+, structural aberrations on 6, 11, 12 and 13. Proto-oncogenes are frequently located close to breakpoints. The proto-oncogene c-K-ras is located on chromosome 12 and an abnormal transcript has recently been implicated in a subset of B-CLL-patients. An extra chromosome 12 as well as multiple chromosomal abnormalities in B-CLL appear to predict a less favourable prognosis. T-CLL is in most patients characterized by an inv(14), an extra 8q and structural abnormalities in chromosome 7. The genes for the specific T-cell receptor as well as the immunoglobulin heavy chain are located on these chromosomes. Chromosomal aberrations appear to have pathogenetic importance in both B-CLL and T-CLL.

Entities:  

Mesh:

Year:  1987        PMID: 3332102     DOI: 10.1016/0268-960x(87)90034-8

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  1 in total

Review 1.  Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia.

Authors:  Maurizio Cavallari; Francesco Cavazzini; Antonio Cuneo; Gian Matteo Rigolin; Antonella Bardi; Eleonora Volta; Aurora Melandri; Elisa Tammiso; Elena Saccenti; Enrico Lista; Francesca Maria Quaglia; Antonio Urso; Michele Laudisi; Elisa Menotti; Luca Formigaro; Melissa Dabusti; Maria Ciccone; Paolo Tomasi; Massimo Negrini
Journal:  Oncotarget       Date:  2018-09-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.